Treatment of Polydrug-Using Opiate Dependents During Withdrawal
- Conditions
- Opiate DependenceDrug DependenceSubstance Withdrawal Syndrome
- Registration Number
- NCT00367874
- Lead Sponsor
- Sorlandet Hospital HF
- Brief Summary
Managed detoxification is a first and necessary step prior to treatment and rehabilitation. Detoxification can be a major obstacle for some patients, and the availability of managed and safe withdrawal is a prerequisite for long-term treatment.
In our clinical practice we have felt the need for a standardised and safe detoxification treatment regimen for our opioid addicts, as dependence on multiple drugs is so common.
Objectives
1. To assess whether a novel standardised treatment regimen - Buprenorphine (BPN) combined with Valproate (VPA) - will result in fewer withdrawal symptoms during detoxification of opiate-polydrug users than the existing treatment regimen, i.e. Clonidine (CLN) combined with Carbamazepine (CBZ).
2. To determine whether there are differences in treatment retention between the BPN/VPA and the CLN/CBZ groups.
3. To assess differences in clinical side-effects and biochemical interactions between the two treatment regimens.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 12
- Polydrug dependency (at least opiate and benzodiazepine dependency)
- No severe psychiatric illness
- No history of epilepsy seizures
- No pregnancy or breastfeeding
- Fertile women must use contraceptives
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Retention in treatment Withdrawal symptoms
- Secondary Outcome Measures
Name Time Method Serum concentration of Valproate and Buprenorphine separately and in combination Urine testing
Trial Locations
- Locations (1)
Sorlandet Hospital HF, Addiction Unit (ARA)
🇳🇴Kristiansand, Vest-Agder, Norway